Novo Nordisk (NYSE:NVO) shares have drawn attention recently as investors look for clues about what might be driving the stock's movement this month. In the absence of major headlines, valuation and market sentiment are coming into focus.

See our latest analysis for Novo Nordisk.

Novo Nordisk has seen its share price slip sharply in recent weeks, with a 19.1% drop over the past month and momentum fading after a stellar run. Over the past year, total shareholder return fell a steep 55%, even as the company’s longer-term five-year total return remains impressively positive. Recent moves reflect shifting risk appetites and a sharper focus on valuation.

If Novo Nordisk’s recent swings have you rethinking your next move, consider exploring innovation across the healthcare landscape. See the full list for free.

With shares trading well below analyst price targets, investors now face a crucial question: is Novo Nordisk undervalued at current levels, or has the market already accounted for all of its future growth potential?

According to bactrian, Novo Nordisk’s current equity price stands far below their fair value estimate, setting the stage for a dramatic potential upside if forecasts hold true. The narrative puts the spotlight squarely on the company’s growth optionality and pipeline innovation, which could reshape its market standing.

Crucially, the market appears to assign little to no value to Novo’s development-stage pipeline beyond Wegovy. A sum-of-the-parts (SOTP) framework suggests that even conservatively discounting the cash flows from Ozempic/Wegovy implies that the pipeline, including oral GLP-1, amycretin, and NASH candidates, is being valued at or near zero.

Read the complete narrative.

How does this view justify such a bold fair value target? The key is a forward-looking forecast built on major breakthroughs, new product launches, and a profit trajectory rarely seen in pharma. Discover which new therapies and calculations make this narrative stand apart from what the market is currently pricing in.

Result: Fair Value of $120.72 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent US policy risks or a further slowdown in Wegovy and Ozempic growth could quickly challenge the case for undervaluation.

Find out about the key risks to this Novo Nordisk narrative.

If you want to challenge this point of view or take a hands-on approach, all the data is at your fingertips. A fresh perspective can be built in minutes. Start now: Do it your way

A great starting point for your Novo Nordisk research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.

Don’t let your next great investment slip past you. The Simply Wall Street Screener is packed with opportunities just waiting for you to take action.

Spot companies offering robust yields and growth by checking out 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 20 dividend stocks with yields > 3% with impressive payouts above 3%.

Catch the momentum in the AI revolution and review these 26 AI penny stocks that are making waves with innovative technology and rapid expansion.

Get ahead of the market by uncovering these 840 undervalued stocks based on cash flows selected for powerful potential based on strong cash flow valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NVO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com